Australia's BARD1 Life Sciences jumps on agreement for cancer research

Inoviq

29/11/2021 04:00

** Shares of medical diagnostics co  BD1.AX  rise as much as
5.8% to A$1.10, on track for their sharpest single day jump
since Nov. 15
    ** BD1 says co has signed a Consultancy and Commercial
Research Agreement with Griffith University in Queensland,
Australia
    ** Agreement to support development of an exosome-based
BARD1 ribonucleic acid (RNA) test for earlier detection of
ovarian and breast cancers  urn:newsml:reuters.com:*:nASX3ZSVwS
    ** Adds agreement will be delivered through Mucosal
Immunology Research Group (MIRG), which has expertise in RNA
analysis, at Griffith University  
    ** More than 326,700 shares change hands, compared with the
30-day average volume of 326,839 shares 
    ** Stock has risen 52.9% this year, as of last close

 (Reporting by Roushni Nair in Bangalore.)
 ((Roushni.Nair@thomsonreuters.com))